181 related articles for article (PubMed ID: 25709040)
21. Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure.
Park H; Chi O; Kim J; Hong S
J Chem Inf Model; 2011 Nov; 51(11):2986-93. PubMed ID: 22017333
[TBL] [Abstract][Full Text] [Related]
22. Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit.
George DM; Breinlinger EC; Friedman M; Zhang Y; Wang J; Argiriadi M; Bansal-Pakala P; Barth M; Duignan DB; Honore P; Lang Q; Mittelstadt S; Potin D; Rundell L; Edmunds JJ
J Med Chem; 2015 Jan; 58(1):222-36. PubMed ID: 25000588
[TBL] [Abstract][Full Text] [Related]
23. Hot spot-based design of small-molecule inhibitors for protein-protein interactions.
Guo W; Wisniewski JA; Ji H
Bioorg Med Chem Lett; 2014 Jun; 24(11):2546-54. PubMed ID: 24751445
[TBL] [Abstract][Full Text] [Related]
24. Fragment-Based Ligand Designing.
Katiyar SP; Malik V; Kumari A; Singh K; Sundar D
Methods Mol Biol; 2018; 1762():123-144. PubMed ID: 29594771
[TBL] [Abstract][Full Text] [Related]
25. Crystallographic fragment screening.
Badger J
Methods Mol Biol; 2012; 841():161-77. PubMed ID: 22222452
[TBL] [Abstract][Full Text] [Related]
26. Structure-guided fragment screening for lead discovery.
Verdonk ML; Hartshorn MJ
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):404-10. PubMed ID: 15338949
[TBL] [Abstract][Full Text] [Related]
27. Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia.
Keserű GM; Erlanson DA; Ferenczy GG; Hann MM; Murray CW; Pickett SD
J Med Chem; 2016 Sep; 59(18):8189-206. PubMed ID: 27124799
[TBL] [Abstract][Full Text] [Related]
28. Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK).
Huard K; Ahn K; Amor P; Beebe DA; Borzilleri KA; Chrunyk BA; Coffey SB; Cong Y; Conn EL; Culp JS; Dowling MS; Gorgoglione MF; Gutierrez JA; Knafels JD; Lachapelle EA; Pandit J; Parris KD; Perez S; Pfefferkorn JA; Price DA; Raymer B; Ross TT; Shavnya A; Smith AC; Subashi TA; Tesz GJ; Thuma BA; Tu M; Weaver JD; Weng Y; Withka JM; Xing G; Magee TV
J Med Chem; 2017 Sep; 60(18):7835-7849. PubMed ID: 28853885
[TBL] [Abstract][Full Text] [Related]
29. The ins and outs of selective kinase inhibitor development.
Müller S; Chaikuad A; Gray NS; Knapp S
Nat Chem Biol; 2015 Nov; 11(11):818-21. PubMed ID: 26485069
[No Abstract] [Full Text] [Related]
30. The rise of fragment-based drug discovery.
Murray CW; Rees DC
Nat Chem; 2009 Jun; 1(3):187-92. PubMed ID: 21378847
[TBL] [Abstract][Full Text] [Related]
31. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
Badrinarayan P; Sastry GN
J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
[TBL] [Abstract][Full Text] [Related]
32. Fragment based drug design: from experimental to computational approaches.
Kumar A; Voet A; Zhang KY
Curr Med Chem; 2012; 19(30):5128-47. PubMed ID: 22934764
[TBL] [Abstract][Full Text] [Related]
33. Automatic tailoring and transplanting: a practical method that makes virtual screening more useful.
Li Y; Zhao Y; Liu Z; Wang R
J Chem Inf Model; 2011 Jun; 51(6):1474-91. PubMed ID: 21520918
[TBL] [Abstract][Full Text] [Related]
34. De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments.
Urich R; Wishart G; Kiczun M; Richters A; Tidten-Luksch N; Rauh D; Sherborne B; Wyatt PG; Brenk R
ACS Chem Biol; 2013 May; 8(5):1044-52. PubMed ID: 23534475
[TBL] [Abstract][Full Text] [Related]
35. Biophysical methods for identifying fragment-based inhibitors of protein-protein interactions.
Pfaff SJ; Chimenti MS; Kelly MJ; Arkin MR
Methods Mol Biol; 2015; 1278():587-613. PubMed ID: 25859978
[TBL] [Abstract][Full Text] [Related]
36. Lessons learned from molecular scaffold analysis.
Hu Y; Stumpfe D; Bajorath J
J Chem Inf Model; 2011 Aug; 51(8):1742-53. PubMed ID: 21755989
[No Abstract] [Full Text] [Related]
37. Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.
Ren L; Grina J; Moreno D; Blake JF; Gaudino JJ; Garrey R; Metcalf AT; Burkard M; Martinson M; Rasor K; Chen H; Dean B; Gould SE; Pacheco P; Shahidi-Latham S; Yin J; West K; Wang W; Moffat JG; Schwarz JB
J Med Chem; 2015 Feb; 58(4):1976-91. PubMed ID: 25603482
[TBL] [Abstract][Full Text] [Related]
38. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
39. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
Hennig M; Ruf A; Huber W
Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
[TBL] [Abstract][Full Text] [Related]
40. Computational discovery of picomolar Q(o) site inhibitors of cytochrome bc1 complex.
Hao GF; Wang F; Li H; Zhu XL; Yang WC; Huang LS; Wu JW; Berry EA; Yang GF
J Am Chem Soc; 2012 Jul; 134(27):11168-76. PubMed ID: 22690928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
